PEN
NEUTRAL
$325.33
Live
Penumbra, Inc. · NYSE
Target $365.79
(+12.4%)
$221.26
52W Range
$362.41
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated May 02, 2026
Market cap
$12.8B
P/E
71.98
ROE
13.8%
Profit margin
12.7%
Debt/Equity
0.15
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Penumbra exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally strong balance sheet characterized by low debt and high liquidity. While the company demonstrates impressive growth metrics, including 38.3% earnings growth and a PEG ratio of 0.74, the current price of $325.33 represents a massive premium over its Graham Number ($60.84) and Intrinsic Value ($133.34). The bullish growth trajectory is currently offset by bearish insider sentiment and a negative technical trend, suggesting the stock may be overextended in the short term.
Key Strengths
Strong growth profile with 38.3% YoY earnings growth and 22.1% revenue growth
Excellent liquidity position with a Current Ratio of 6.64 and Quick Ratio of 4.01
Very low leverage with a Debt/Equity ratio of 0.15
High profitability margins, specifically a Gross Margin of 67.14%
Consistent track record of beating earnings estimates over the last 4 quarters
Key Risks
Extreme valuation premium relative to defensive fair value (Graham Number)
Bearish insider activity with 9 sell transactions and 0 buys in the last 6 months
High P/E ratio of 71.98 makes the stock sensitive to any growth deceleration
Bearish technical trend (0/100 score)
Significant gap between current market price and growth-based intrinsic value
AI Fair Value Estimate
Based on comprehensive analysis
$158.5
-51.3% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
52
Moderate
25
88
82
65
0
AI Verdict
High-Growth Premium
Key drivers: Strong EPS growth, Low debt, Extreme valuation gap, Insider selling
Confidence
90%
Value
25/100
Ref P/E 71.98, PEG 0.74, Graham Number $60.84
Positives
- PEG ratio of 0.74 suggests growth justifies some premium
Watchpoints
- P/E of 71.98 is very high
- Price is >5x the Graham Number
Future
88/100
Ref Revenue Growth 22.10%, Earnings Growth 38.30%
Positives
- Strong YoY Revenue and Earnings growth
- Consistent earnings surprises
Watchpoints
- High expectations baked into price
Past
82/100
Ref Historical Earnings Track Record and Price Performance
Positives
- Strong 6-month price performance (+43.1%)
- Long-term history of earnings beats
Watchpoints
- Recent 1-week and 1-month price dip
Health
65/100
Ref Piotroski F-Score 4/9, Debt/Equity 0.15
Positives
- Very low Debt/Equity (0.15)
- Exceptional Current Ratio (6.64)
Watchpoints
- Piotroski F-Score is only 4/9 (Stable, not Strong)
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$325.33
Analyst Target
$365.79
Upside/Downside
+12.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PEN and closest competitors.
Updated 2026-05-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PEN
Penumbra, Inc.
Primary
|
+9.1% | +15.6% | +11.5% | +43.1% | -1.1% | -1.4% |
|
GMED
Globus Medical, Inc.
Peer
|
+30.6% | +61.2% | +29.0% | +48.1% | +11.8% | -3.2% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.7% | -45.5% | -2.1% | +33.1% | +6.6% | -9.2% |
|
FMS
Fresenius Medical Care AG
Peer
|
-34.1% | +6.8% | -3.1% | -16.4% | +2.3% | -2.7% |
|
IONS
Ionis Pharmaceuticals, Inc.
Peer
|
+83.9% | +101.9% | +181.4% | +7.4% | +0.5% | +0.5% |
PEN
Penumbra, Inc.
Primary
5Y
+9.1%
3Y
+15.6%
1Y
+11.5%
6M
+43.1%
1M
-1.1%
1W
-1.4%
GME
Globus Medical, Inc.
Peer
5Y
+30.6%
3Y
+61.2%
1Y
+29.0%
6M
+48.1%
1M
+11.8%
1W
-3.2%
ALG
Align Technology, Inc.
Peer
5Y
-70.7%
3Y
-45.5%
1Y
-2.1%
6M
+33.1%
1M
+6.6%
1W
-9.2%
FMS
Fresenius Medical Care AG
Peer
5Y
-34.1%
3Y
+6.8%
1Y
-3.1%
6M
-16.4%
1M
+2.3%
1W
-2.7%
ION
Ionis Pharmaceuticals, Inc.
Peer
5Y
+83.9%
3Y
+101.9%
1Y
+181.4%
6M
+7.4%
1M
+0.5%
1W
+0.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
71.98
Forward P/E
51.01
PEG Ratio
0.74
P/B Ratio
8.94
P/S Ratio
9.12
EV/Revenue
8.86
EV/EBITDA
60.24
Market Cap
$12.8B
Profitability
Profit margins and return metrics
Profit Margin
12.66%
Operating Margin
15.37%
Gross Margin
67.14%
ROE
13.78%
ROA
7.04%
Growth
Revenue and earnings growth rates
Revenue Growth
+22.1%
Earnings Growth
+38.3%
Q/Q Revenue Growth
+22.14%
Q/Q Earnings Growth
+40.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.15
Low debt
Current Ratio
6.64
Strong
Quick Ratio
4.01
Excellent
Cash/Share
$13.88
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
68.0%
Op. Margin
15.4%
Net Margin
12.3%
Total Assets
$1.8B
Liabilities
$0.4B
Equity
$1.4B
Debt/Equity
0.28x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
79%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-13
$N/A
2026-02-25
$1.18
+6.1% surprise
2025-11-05
$0.97
+5.3% surprise
2025-07-29
$0.86
+4.7% surprise
Healthcare Sector Comparison
Comparing PEN against 595 companies in the Healthcare sector
(36 bullish, 188 neutral, 371 bearish)
P/E Ratio
71.98
This Stock
vs
71.35
Sector Avg
+0.9%
(Premium)
Return on Equity (ROE)
13.78%
This Stock
vs
-87.4%
Sector Avg
-115.8%
(Below Avg)
Profit Margin
12.66%
This Stock
vs
-15.81%
Sector Avg
-180.1%
(Weaker)
Debt to Equity
0.15
This Stock
vs
2.56
Sector Avg
-94.0%
(Less Debt)
Revenue Growth
22.1%
This Stock
vs
118.3%
Sector Avg
-81.3%
(Slower)
Current Ratio
6.64
This Stock
vs
4.36
Sector Avg
+52.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PEN
Penumbra, Inc.
|
NEUTRAL | $12.8B | 71.98 | 13.8% | 12.7% | $325.33 | |
|
GMED
Globus Medical, Inc.
|
BULLISH | $12.71B | 23.9 | 12.3% | 18.3% | $93.7 | Compare |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $12.7B | 31.32 | 10.4% | 10.2% | $177.28 | Compare |
|
FMS
Fresenius Medical Care AG
|
BULLISH | $12.44B | 11.56 | 7.9% | 5.0% | $22.77 | Compare |
|
IONS
Ionis Pharmaceuticals, Inc.
|
BEARISH | $12.42B | - | -70.8% | -40.4% | $75.17 | Compare |
PEN
Penumbra, Inc.
NEUTRAL
Mkt Cap
$12.8B
P/E
72.0
ROE
13.8%
Price
$325.33
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | GREWAL HARPREET SINGH | Director | Sale | 100 | $32,822 |
| 2026-03-02 | YUEN MAGGIE S. | Chief Financial Officer | Sale | 2,432 | $832,474 |
| 2026-02-17 | ROBERTS JOHANNA | General Counsel | Stock Award | 5,260 | - |
| 2026-02-17 | YUEN MAGGIE S. | Chief Financial Officer | Stock Award | 5,260 | - |
| 2026-02-17 | SHIU LAMBERT | Officer | Stock Award | 4,600 | - |
| 2026-02-17 | NARAYAN SHRUTHI | President | Stock Award | 5,260 | - |
| 2026-02-13 | GREWAL HARPREET SINGH | Director | Stock Award | 589 | - |
| 2026-02-13 | WILDER THOMAS C III | Director | Stock Award | 589 | - |
| 2026-02-13 | O'ROURKE BRIDGET A | Director | Stock Award | 589 | - |
| 2026-02-13 | LEEDS JANET | Director | Stock Award | 589 | - |
| 2026-02-13 | SARNA SURBHI | Director | Stock Award | 589 | - |
| 2026-02-13 | BOSE ARANI | Director | Stock Award | 589 | - |
| 2026-01-06 | GREWAL HARPREET SINGH | Director | Sale | 186 | $58,151 |
| 2026-01-02 | WILDER THOMAS C III | Director | Sale | 186 | $57,794 |
| 2025-12-11 | BOSE ARANI | Director | Sale | 15,000 | $4,632,292 |
GREWAL HARPREET SINGH
Director
2026-04-02
100 shares
·
$32,822
YUEN MAGGIE S.
Chief Financial Officer
2026-03-02
2,432 shares
·
$832,474
ROBERTS JOHANNA
General Counsel
2026-02-17
5,260 shares
YUEN MAGGIE S.
Chief Financial Officer
2026-02-17
5,260 shares
SHIU LAMBERT
Officer
2026-02-17
4,600 shares
NARAYAN SHRUTHI
President
2026-02-17
5,260 shares
GREWAL HARPREET SINGH
Director
2026-02-13
589 shares
WILDER THOMAS C III
Director
2026-02-13
589 shares
O'ROURKE BRIDGET A
Director
2026-02-13
589 shares
LEEDS JANET
Director
2026-02-13
589 shares
SARNA SURBHI
Director
2026-02-13
589 shares
BOSE ARANI
Director
2026-02-13
589 shares
GREWAL HARPREET SINGH
Director
2026-01-06
186 shares
·
$58,151
WILDER THOMAS C III
Director
2026-01-02
186 shares
·
$57,794
BOSE ARANI
Director
2025-12-11
15,000 shares
·
$4,632,292
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
8-K
10-Q
8-K
8-K
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
14 analysts
Evercore ISI Group
2026-02-26
Outperform
Outperform
RBC Capital
2026-01-20
Outperform
Sector Perform
Canaccord Genuity
2026-01-20
Buy
Hold
Jefferies
2026-01-16
Buy
Hold
Needham
2026-01-16
Buy
Hold
Citigroup
2026-01-16
Buy
Neutral
Leerink Partners
2026-01-16
Outperform
Market Perform
Baird
2026-01-16
Outperform
Neutral
BTIG
2026-01-16
Buy
Neutral
Truist Securities
2026-01-16
Buy
Hold
Past News Coverage
Recent headlines mentioning PEN from our newsroom.
Newest → oldest
No matching news yet.